Tirzepatide has emerged as a groundbreaking treatment for type 2 diabetes, offering promising results. However, the expense of this innovative drug and its access have become key topics for patients and healthcare practitioners. While tirzepatide has been cleared by regulatory agencies, its expensive nature presents a significant obstacle to many.